High Cyclin B1 Expression is Associated with Poor Survival in Breast Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2009 Mar 19

PMID 19293801

Citations 68

Authors

K Aaltonen

R-M Amini

P Heikkila

K Aittomaki

A Tamminen

H Nevanlinna

C Blomqvist

Affiliations

Soon will be listed here.

Abstract

Cyclin B1 regulates the G(2)-M transition of the cell cycle. Cyclin B1 expression is higher in premalignant and malignant than normal breast lesions. Correlation of cyclin B1 expression with other histopathological variables and prognostic role in breast cancer are not fully understood. Traditionally used prognostic criteria identify large subset of patients to receive adjuvant chemotherapy and to be exposed to adverse effects. A reliable and simple method helping prognostic evaluation in breast cancer is needed. We analysed cyclin B1 expression on 1348 invasive breast cancers and studied correlations with other histopathological variables and survival. High cyclin B1 correlated with high tumour grade, large tumour size and positive nodal status, oestrogen and progesterone receptor negativity, positive HER2 and p53 status, young age at diagnosis, and high cyclin E, cyclin A and Ki67 expression. Among patients not given adjuvant chemotherapy high cyclin B1 was a strong predictor of shorter overall and metastasis-free survival (RR 3.74, P<0.0005 and RR 3.51, P<0.0005, respectively), and remained as an independent prognostic factor also in multivariate analysis (RR 1.80, P=0.04 and RR 2.31, P=0.02, respectively). This study suggests high cyclin B1 associates with aggressive phenotype and is an independent prognostic factor in breast cancer.

Citing Articles

Copper is essential for cyclin B1-mediated CDK1 activation.

Wang J, Yang D, Yu H, Jin J, Nie Y, Zhang S Nat Commun. 2025; 16(1):2288.

PMID: 40055333 PMC: 11889272. DOI: 10.1038/s41467-025-57538-7.

Bioinformatics-Driven Investigations of Signature Biomarkers for Triple-Negative Breast Cancer.

Handa S, Puri S, Chatterjee M, Puri V Bioinform Biol Insights. 2025; 19:11779322241271565.

PMID: 40034579 PMC: 11873876. DOI: 10.1177/11779322241271565.

Integrated analysis of cell cycle and p53 signaling pathways related genes in breast, colorectal, lung, and pancreatic cancers: implications for prognosis and drug sensitivity for therapeutic potential.

Khan J, Ghosh P, Bajpai U, Dwivedi K, Saluja D Discov Oncol. 2024; 15(1):832.

PMID: 39715832 PMC: 11666898. DOI: 10.1007/s12672-024-01712-8.

Proapoptotic role of CDK1 in overcoming paclitaxel resistance in ovarian cancer cells in response to combined treatment with paclitaxel and duloxetine.

Kim G, Jang S, Ahn S, Kim S, Park C, Seong M Cancer Cell Int. 2024; 24(1):409.

PMID: 39702300 PMC: 11660910. DOI: 10.1186/s12935-024-03607-8.

Nuclear miRNAs as transcriptional regulators in processes related to various cancers (Review).

Wang Z, Zhang Y, Li K Int J Oncol. 2024; 64(5).

PMID: 38606502 PMC: 11015916. DOI: 10.3892/ijo.2024.5644.

References

Bryant J, Fisher B, Gunduz N, Costantino J, Emir B . S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer. Breast Cancer Res Treat. 1999; 51(3):239-53. DOI: 10.1023/a:1006184428857. View

Ahlin C, Aaltonen K, Amini R, Nevanlinna H, Fjallskog M, Blomqvist C . Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values?. Histopathology. 2007; 51(4):491-8. DOI: 10.1111/j.1365-2559.2007.02798.x. View

Suzuki T, Urano T, Miki Y, Moriya T, Akahira J, Ishida T . Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. Cancer Sci. 2007; 98(5):644-51. PMC: 11159733. DOI: 10.1111/j.1349-7006.2007.00444.x. View

Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J . Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res. 2005; 11(14):5098-103. DOI: 10.1158/1078-0432.CCR-05-0173. View

Look M, van Putten W, Duffy M, Harbeck N, Christensen I, Thomssen C . Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst. 2002; 94(2):116-28. DOI: 10.1093/jnci/94.2.116. View

Buyse M, Loi S, Veer L, Viale G, Delorenzi M, Glas A . Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006; 98(17):1183-92. DOI: 10.1093/jnci/djj329. View

Kilpivaara O, Bartkova J, Eerola H, Syrjakoski K, Vahteristo P, Lukas J . Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer. 2004; 113(4):575-80. DOI: 10.1002/ijc.20638. View

Sherr C . Cancer cell cycles. Science. 1996; 274(5293):1672-7. DOI: 10.1126/science.274.5293.1672. View

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

10.

Volpi A, Bacci F, Angelo Paradiso , Saragoni L, Scarpi E, Ricci M . Prognostic relevance of histological grade and its components in node-negative breast cancer patients. Mod Pathol. 2004; 17(9):1038-44. DOI: 10.1038/modpathol.3800161. View

11.

Innocente S, Abrahamson J, Cogswell J, Lee J . p53 regulates a G2 checkpoint through cyclin B1. Proc Natl Acad Sci U S A. 1999; 96(5):2147-52. PMC: 26751. DOI: 10.1073/pnas.96.5.2147. View

12.

Aaltonen K, Ahlin C, Amini R, Salonen L, Fjallskog M, Heikkila P . Reliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slides. Br J Cancer. 2006; 94(11):1697-702. PMC: 2361315. DOI: 10.1038/sj.bjc.6603147. View

13.

Yoshida T, Tanaka S, Mogi A, Shitara Y, Kuwano H . The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol. 2004; 15(2):252-6. DOI: 10.1093/annonc/mdh073. View

14.

J van t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6. DOI: 10.1038/415530a. View

15.

Nozoe T, Korenaga D, Kabashima A, Ohga T, Saeki H, Sugimachi K . Significance of cyclin B1 expression as an independent prognostic indicator of patients with squamous cell carcinoma of the esophagus. Clin Cancer Res. 2002; 8(3):817-22. View

16.

Bast Jr R, Ravdin P, Hayes D, Bates S, Fritsche Jr H, Jessup J . 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001; 19(6):1865-78. DOI: 10.1200/JCO.2001.19.6.1865. View

17.

Ikuerowo S, Kuczyk M, Mengel M, van der Heyde E, Shittu O, Vaske B . Alteration of subcellular and cellular expression patterns of cyclin B1 in renal cell carcinoma is significantly related to clinical progression and survival of patients. Int J Cancer. 2006; 119(4):867-74. DOI: 10.1002/ijc.21869. View

18.

Simpson J, Gray R, Dressler L, COBAU C, Falkson C, Gilchrist K . Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol. 2000; 18(10):2059-69. DOI: 10.1200/JCO.2000.18.10.2059. View

19.

Elston C, Ellis I . Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 2002; 41(3A):154-61. View

20.

Shen M, Feng Y, Gao C, Tao D, Hu J, Reed E . Detection of cyclin b1 expression in g(1)-phase cancer cell lines and cancer tissues by postsorting Western blot analysis. Cancer Res. 2004; 64(5):1607-10. DOI: 10.1158/0008-5472.can-03-3321. View